Brainstorm Cell grants 100,000 RSUs to officer

Patlis Alla reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Patlis Alla reported acquisition or exercise transactions in this Form 4 filing.

Brainstorm Cell Therapeutics Inc. reported that officer Alla Patlis received a grant of 100,000 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost per share. Following this award, Patlis directly holds 144,349 shares.

According to the terms, 50% of the RSU award vests on the grant date and the remaining 50% vests on the six‑month anniversary of the grant, as long as Patlis remains employed by the company through each vesting date. This filing reflects a compensation-related equity grant rather than an open‑market share purchase or sale.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Patlis Alla

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	100,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 144,349 shares (Direct)

Footnotes (1)

1. F1. Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

RSUs granted: 100,000 shares Total shares after grant: 144,349 shares Grant price per share: $0.0000 per share

3 metrics

RSUs granted 100,000 shares Restricted stock units of Common Stock awarded to Alla Patlis

Total shares after grant 144,349 shares Direct holdings of Alla Patlis following the RSU award

Grant price per share $0.0000 per share Reported transaction price for the RSU award

Key Terms

restricted stock units ("RSUs"), vest, Plan

3 terms

restricted stock units ("RSUs") financial

"Represents shares of restricted stock units ("RSUs") awarded under the Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Plan financial

"Represents shares of restricted stock units ("RSUs") awarded under the Plan."

FAQ

What did Alla Patlis report in the latest Form 4 for BCLI?

Alla Patlis reported receiving a grant of 100,000 restricted stock units (RSUs) of Brainstorm Cell Therapeutics Common Stock. The award is a compensation-related equity grant, not an open-market transaction, and increases total direct holdings to 144,349 shares after the grant.

How many BCLI shares does Alla Patlis hold after this RSU grant?

After the grant, Alla Patlis directly holds 144,349 shares of Brainstorm Cell Therapeutics Common Stock. This total includes the newly awarded 100,000 RSUs, which are subject to vesting conditions tied to continued employment with the company over the defined schedule.

What are the vesting terms of Alla Patlis’s 100,000 BCLI RSUs?

The 100,000 RSUs vest in two equal parts: 50% on the grant date and the remaining 50% on the six‑month anniversary of the grant date. Vesting requires that Alla Patlis remain employed by Brainstorm Cell Therapeutics through each applicable vesting date.

Was any cash paid for the BCLI RSUs granted to Alla Patlis?

No cash was paid for these RSUs, as the reported price per share is $0.0000. The award represents stock-based compensation under the company’s plan, rather than a purchase of shares in the open market or through a cash-funded transaction.

Is Alla Patlis’s BCLI Form 4 transaction a buy or a sale?

The Form 4 shows an acquisition through a grant or award, classified under transaction code “A.” It reflects 100,000 RSUs awarded as compensation, not a market buy or sale. There are no reported dispositions or open-market trades in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patlis Alla

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		100,000(1)	A	$0.00	144,349	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Remarks:

Interim Chief Financial Officer & Controller

	/s/ Alla Patlis	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)